UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Journal of molecular and cellular cardiology, ISSN 0022-2828, 2015, Volume 84, pp. 24 - 35
Cardiovascular | Myocardial infarction | Splenic remodeling | Resolution of inflammation | Metabololipidomics | Resolvin D1 | Neutrophils | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Cell Biology | Cell Count | Male | Myocardial Infarction - diagnostic imaging | Spleen - drug effects | Extracellular Matrix - genetics | Inflammation - complications | Pulmonary Edema - physiopathology | Inflammation - drug therapy | Pulmonary Edema - complications | Receptors, Formyl Peptide - metabolism | Ultrasonography | Myocardial Infarction - physiopathology | Cell Polarity - drug effects | Spleen - pathology | Neutrophil Infiltration - drug effects | Ventricular Function - drug effects | Docosahexaenoic Acids - therapeutic use | Arachidonate 5-Lipoxygenase - metabolism | Docosahexaenoic Acids - chemistry | Extracellular Matrix - drug effects | Mice, Inbred C57BL | Cardiomegaly - diagnostic imaging | Cardiomegaly - drug therapy | Cardiomegaly - physiopathology | Pulmonary Edema - drug therapy | Cardiomegaly - complications | Collagen - metabolism | Docosahexaenoic Acids - pharmacology | Myocardial Infarction - complications | Macrophages - metabolism | Animals | Myocardial Infarction - drug therapy | Heart Ventricles - physiopathology | Prostaglandin-Endoperoxide Synthases - metabolism | Macrophages - drug effects | Ventricular Remodeling - drug effects | Heart Ventricles - drug effects | Inflammation | Heart attack | Index Medicus | metabololipidomics | liposomes | myocardial infarction | splenic remodeling | neutrophils | resolution of inflammation
Journal Article
Scientific reports, ISSN 2045-2322, 2015, Volume 5, Issue 1, pp. 8794 - 8794
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Receptors, Angiotensin - metabolism | Diabetic Cardiomyopathies - metabolism | Diabetic Cardiomyopathies - drug therapy | Apoptosis - drug effects | Transforming Growth Factor beta1 - metabolism | Cardiomegaly - etiology | Cardiomegaly - pathology | Male | Peptide Fragments - pharmacology | Perindopril - administration & dosage | Perindopril - pharmacology | Heart Ventricles - ultrastructure | Peptidyl-Dipeptidase A - metabolism | Angiotensin I - pharmacology | Collagen - biosynthesis | p38 Mitogen-Activated Protein Kinases - metabolism | Phosphorylation - drug effects | Drug Therapy, Combination | Heart Ventricles - pathology | Disease Models, Animal | Fibroblasts - metabolism | Echocardiography | Peptide Fragments - administration & dosage | Angiotensin I - administration & dosage | Cardiomegaly - drug therapy | Rats | Diabetic Cardiomyopathies - diagnosis | Ventricular Dysfunction, Left - prevention & control | Blood Glucose - drug effects | Animals | Ventricular Dysfunction, Left - drug therapy | Mitogen-Activated Protein Kinase 3 - metabolism | Cell Differentiation - drug effects | Fibroblasts - drug effects | Cell Communication - drug effects | Fibrosis | Cell Proliferation - drug effects | Fibroblasts - cytology | Hemodynamics - drug effects | Oxidative Stress - drug effects | Heart Ventricles - drug effects | Mitogen-Activated Protein Kinase 1 - metabolism | Heart | Enzymes | Cardiomyopathy | Diabetes mellitus | Rodents | Angiotensin | Diabetes | Ventricle | Angiotensin II | Hypertrophy | Apoptosis | Index Medicus
Journal Article
Blood pressure, ISSN 0803-7051, 2010, Volume 19, Issue 3, pp. 169 - 175
left atrial size | hypertension | prognosis | Atrial fibrillation | Hypertension | Prognosis | Left atrial size | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Antihypertensive Agents - pharmacology | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Hypertension - drug therapy | Male | Risk | Cardiovascular Diseases - complications | Electrocardiography | Female | Blood Pressure - drug effects | Heart Atria - physiopathology | Hypertrophy, Left Ventricular - drug therapy | Atenolol - pharmacology | Heart Rate | Atrial Fibrillation - drug therapy | Cardiomegaly - drug therapy | Losartan - pharmacology | Antihypertensive Agents - therapeutic use | Cardiomegaly - complications | Hypertension - physiopathology | Arrhythmias, Cardiac - drug therapy | Atenolol - therapeutic use | Atrial Fibrillation - epidemiology | Heart Ventricles - physiopathology | Hypertrophy, Left Ventricular - complications | Losartan - therapeutic use | Hypertension - complications | Aged | Arrhythmias, Cardiac - complications | Hypertrophy, Left Ventricular - physiopathology | Atrial Fibrillation - prevention & control | Index Medicus | Heart Atria/physiopathology | Cardiac/complications/drug therapy | Hypertension/complications/drug therapy/physiopathology | Losartan/pharmacology/therapeutic use | Heart Ventricles/physiopathology | Cardiomegaly/complications/drug therapy | Cardiovascular Diseases/complications/drug therapy | Atenolol/pharmacology/therapeutic use | Kardiologi | Cardiac and Cardiovascular Systems | Blood Pressure/drug effects | Atrial Fibrillation/drug therapy/epidemiology/prevention & control | Antihypertensive Agents/pharmacology/therapeutic use | Left Ventricular/complications/drug therapy/physiopathology | Arrhythmias | Hypertrophy
Journal Article
Journal of molecular and cellular cardiology, ISSN 0022-2828, 09/2018, Volume 122, pp. 114 - 124
Cardiac hypertrophy | Testosterone | Signaling | Myocardial remodeling | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Cell Biology | Human Umbilical Vein Endothelial Cells | Cell Line | Neovascularization, Physiologic - drug effects | Gene Expression - drug effects | Humans | Ventricular Function, Left - drug effects | Cardiomegaly - drug therapy | Rats | Male | Myocardium - pathology | Rats, Sprague-Dawley | Animals | Myocardial Infarction - drug therapy | Analysis of Variance | Muscle Contraction - drug effects | Fibroblasts - drug effects | Fibrosis | Androgen Antagonists - therapeutic use | Finasteride - therapeutic use | Mice | Induced Pluripotent Stem Cells | Ventricular Remodeling - drug effects | Dihydrotestosterone - metabolism | Endothelial Cells - drug effects | Heart | Finasteride | Analysis | Genes | Health aspects | Heart attack | Index Medicus
Journal Article
Future medicinal chemistry, ISSN 1756-8919, 10/2015, Volume 7, Issue 15, pp. 2065 - 2086
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Chemistry, Medicinal | Science & Technology | Neoplasms - metabolism | Small Molecule Libraries - pharmacology | Asthma - metabolism | Humans | JNK Mitogen-Activated Protein Kinases - metabolism | Molecular Targeted Therapy | Neurodegenerative Diseases - drug therapy | Protein Kinase Inhibitors - chemistry | MAP Kinase Signaling System - genetics | JNK Mitogen-Activated Protein Kinases - genetics | Autoimmune Diseases - metabolism | Autoimmune Diseases - drug therapy | JNK Mitogen-Activated Protein Kinases - antagonists & inhibitors | Cardiomegaly - drug therapy | Diabetes Mellitus - drug therapy | Small Molecule Libraries - therapeutic use | Diabetes Mellitus - metabolism | Neurodegenerative Diseases - metabolism | Asthma - drug therapy | Neoplasms - drug therapy | Small Molecule Libraries - chemistry | Animals | MAP Kinase Signaling System - drug effects | Protein Kinase Inhibitors - therapeutic use | Protein Kinase Inhibitors - pharmacology | Cardiomegaly - metabolism
Journal Article
European journal of heart failure, ISSN 1388-9842, 2016, Volume 18, Issue 5, pp. 457 - 468
Heart failure | Antimir | MicroRNAs | Circulation | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Biomarkers - metabolism | Acute Disease | Prognosis | Humans | Cardiomegaly - drug therapy | Heart Failure - physiopathology | Cardiomegaly - physiopathology | MicroRNAs - metabolism | Myocardium - pathology | Heart Failure - metabolism | Molecular Targeted Therapy | Heart Failure - drug therapy | Stroke Volume | Fibrosis | Chronic Disease | Cardiomegaly - metabolism | Index Medicus
Journal Article
The Journal of pharmacology and experimental therapeutics, ISSN 0022-3565, 11/2010, Volume 335, Issue 2, pp. 266 - 272
Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Primary Myelofibrosis - drug therapy | Cystic Fibrosis - enzymology | Kidney Diseases - pathology | Humans | Cardiomegaly - drug therapy | Cystic Fibrosis - pathology | Scleroderma, Systemic - pathology | Kidney Diseases - drug therapy | Cardiomegaly - pathology | Histone Deacetylases - metabolism | Cardiomegaly - enzymology | Kidney Diseases - enzymology | Primary Myelofibrosis - pathology | Primary Myelofibrosis - enzymology | Scleroderma, Systemic - enzymology | Fibrosis | Idiopathic Pulmonary Fibrosis - pathology | Histone Deacetylase Inhibitors - therapeutic use | Idiopathic Pulmonary Fibrosis - enzymology | Cystic Fibrosis - drug therapy | Idiopathic Pulmonary Fibrosis - drug therapy | Scleroderma, Systemic - drug therapy
Journal Article
American journal of hypertension, ISSN 0895-7061, 12/2015, Volume 28, Issue 12, pp. 1409 - 1417
angiotensin | blood pressure | cardiovascular protection | neprilysin | dual inhibition | hypertension | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Fibrosis - drug therapy | Tetrazoles - pharmacology | Sodium, Dietary - adverse effects | Angiotensin Receptor Antagonists - pharmacology | Endothelium, Vascular - drug effects | Hypertension - drug therapy | Male | Aminobutyrates - pharmacology | Cyclic GMP - blood | Aminobutyrates - therapeutic use | Hypertension - etiology | Valsartan - pharmacology | Hypertension - blood | Valsartan - therapeutic use | Inflammation - drug therapy | Blood Pressure - drug effects | Vascular Remodeling - drug effects | Drug Evaluation, Preclinical | Rats, Inbred SHR | Cardiomegaly - drug therapy | Sodium, Dietary - urine | Myocardium - pathology | Random Allocation | Animals | Neprilysin - antagonists & inhibitors | Heart - drug effects | Tetrazoles - therapeutic use | Oxidative Stress - drug effects | Angiotensin Receptor Antagonists - therapeutic use | Circadian Rhythm - drug effects | Hypertension | Care and treatment | Cardiac patients | Angiotensin II receptor blockers | Dosage and administration | Cardiovascular diseases | Health aspects | Risk factors | Index Medicus
Journal Article
Journal of cardiovascular pharmacology, ISSN 0160-2446, 10/2014, Volume 64, Issue 4, pp. 293 - 305
Heart failure | Hypertension | Camkii | Reactive oxygen species | Calcium | Calcineurin | Angiotensin receptor blockers | Biased agonists | Left ventricular | Vitamin | AKT | Remodeling | Beta blockers | NFAT | Guanylatecyclase stimulators | Signaling | Nitric oxide | CGMP | Angiotensin II | Hypertrophy | Cardiac & Cardiovascular Systems | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Humans | Cardiomegaly - drug therapy | Antihypertensive Agents - administration & dosage | Cardiomegaly - pathology | Clinical Trials as Topic | Heart Failure - metabolism | Heart Failure - pathology | Antihypertensive Agents - therapeutic use | Molecular Targeted Therapy | Cardiomegaly - complications | Heart Failure - prevention & control | Heart Failure - etiology | Ventricular Remodeling - drug effects | Cardiomegaly - metabolism | Index Medicus
Journal Article